United States · FDA National Drug Code directory
FLUARIX 2026/2027
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 58160-725_2d728e3c-d550-47fb-8fa9-3ce0f244512b
- Product NDC
- 58160-725
- Form
- SUSPENSION
- Composition / generic term
- influenza virus vaccine
- Labeler
- GlaxoSmithKline Biologicals SA
- Marketing category
- BLA
- Marketing start / end (source format)
- 20260701 / 20270630
Source-listed ingredients
- INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) — 15 ug/.5mL
- INFLUENZA A VIRUS A/CROATIA/10136RV/2023 X-425A (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED) — 15 ug/.5mL
- INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 BVR-26 ANTIGEN (FORMALDEHYDE INACTIVATED) — 15 ug/.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 10 SYRINGE in 1 CARTON (58160-725-52) / .5 mL in 1 SYRINGE (58160-725-41) · 58160-725-52
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →